Standard of Care: The 2025 Consensus Guidelines

The approach to treating Persistent Idiopathic Facial Pain (PIFP) has undergone a major shift. In 2025, a landmark international study (the Delphi Consensus) established new, rigorous guidelines for the standard of care ^[1]. This consensus moved away from treating the face as the source of the problem and toward a multidisciplinary approach that treats the overactive central nervous system ^[1].

The Golden Rule: Avoid Invasive Procedures

Perhaps the most important recommendation from the latest guidelines is a strong warning: invasive surgical interventions are not recommended ^[1].

Because PIFP is a nociplastic condition (meaning the issue is with how the brain processes pain signals), “fixing” the hardware of your face through tooth extractions, root canals, or nerve surgeries does not address the underlying cause ^[2]. In many cases, these invasive procedures can actually worsen the condition by providing further trauma to an already hypersensitive nervous system ^[3].

The Pharmacological Approach

The goal of medication in PIFP is to “turn down the volume” of the pain signals in the brain and spinal cord ^[4]. The 2025 guidelines highlight several classes of medications:

1. Tricyclic Antidepressants (TCAs): Medications like amitriptyline are often considered first-line options because they help modulate pain pathways in the brain ^[1].
2. SNRIs: Serotonin-norepinephrine reuptake inhibitors (like duloxetine) are also recommended for their ability to strengthen the brain’s natural pain-braking system ^[1].
3. Gabapentinoids: Drugs like gabapentin or pregabalin may be used to stabilize overactive electrical signals in the nerves ^[1].

It is important to know that these medications do not work immediately. They require a gradual “titration” (slowly increasing the dose) over several weeks to show their full benefit, and they may cause temporary side effects like drowsiness or dizziness while your body adjusts ^[1].

Important Note on Opioids: Expert consensus strongly advises that opioids should generally be avoided ^[1]. They are often ineffective for nociplastic facial pain and can lead to a cycle of increased sensitivity and long-term side effects ^[1].

Non-Pharmacological Interventions

The latest standard of care recognizes that medication is only one piece of the puzzle. A successful plan is multidisciplinary and includes:

• Patient Education: Understanding the biological mechanism of your pain is a therapeutic intervention in itself, as it reduces the fear and stress that can amplify pain signals ^[1][2].
• Behavioral Therapies: Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT) are recommended to help patients manage the psychological toll of chronic pain and improve daily functioning ^[1].
• Physical Therapy/Physiotherapy: Gentle, specialized physical therapy can help manage the secondary muscle tension that often accompanies facial pain ^[1].

Managing Expectations

The 2025 guidelines emphasize a shift in how we define “success.” While the complete elimination of pain is the ultimate hope, it is statistically rare in chronic nociplastic conditions ^[1]. Instead, the primary goal of treatment is improving your quality of life and ability to function ^[1]. By focusing on better sleep, returning to social activities, and reducing the distress caused by the pain, patients can regain a sense of control over their lives.

Treatment is a marathon, not a sprint. It involves finding the right combination of “system-calming” strategies that work for your unique nervous system ^[1][2].